文献速递临床免疫临床血液与体液

Euroimmun CXCL13 ELISA与ReaScan侧流免疫分析诊断莱姆神经疏螺旋体病的比较分析

Comparative Analysis of the Euroimmun CXCL13 Enzyme-Linked Immunosorbent Assay and the ReaScan Lateral Flow Immunoassay for Diagnosis of Lyme Neuroborreliosis.
PubMed 文献 · J Clin Microbiol · 2020-08-24

该双中心病例对照研究纳入90例患者脑脊液样本(34例确诊LNB、10例可能LNB、46例非LNB中枢神经系统疾病),比较Euroimmun CXCL13 ELISA与ReaScan CXCL13侧流免疫分析(LFA)的诊断性能。ELISA敏感性100%、特异性84.8%(cutoff 78.6 pg/ml,AUC 0.93);LFA敏感性91.2%、特异性93.5%(cutoff arbitrary value 22.5,AUC 0.94);两者相关性r=0.89。LFA优势为出结果更快。

要点

  • CXCL13 ELISA对确诊LNB敏感性100%、特异性84.8%,cutoff 78.6 pg/ml。
  • CXCL13 LFA敏感性91.2%、特异性93.5%,cutoff arbitrary value 22.5。
  • 两种方法相关性r=0.89,LFA出结果时间更短。

核心结论

  • CXCL13 ELISA与CXCL13 LFA在确诊LNB患者脑脊液CXCL13检测中为可比的诊断工具,LFA优势为出结果更快。

研究设计与样本

  • 双中心病例对照研究,纳入90例患者脑脊液样本:34例确诊LNB、10例可能LNB、46例非LNB中枢神经系统疾病对照。
  • 患者分类遵循欧洲神经病学联盟(EFNS)LNB指南。

主要发现

  • CXCL13 ELISA在全部确诊LNB患者中检出CXCL13升高(中位数1,409 pg/ml),非LNB对照中位数20.7 pg/ml,P < 0.0001。
  • CXCL13 LFA在31例确诊LNB患者中检出CXCL13升高(中位数arbitrary value 223.5),非LNB对照中位数arbitrary value 0,P < 0.0001。
  • ELISA与LFA所测CXCL13水平相关性强(Spearman r = 0.89;P < 0.0001)。

关键数值与推荐

  • CXCL13 ELISA:cutoff 78.6 pg/ml,敏感性100%,特异性84.8%,AUC 0.93。
  • CXCL13 LFA:cutoff arbitrary value 22.5,敏感性91.2%,特异性93.5%,AUC 0.94。

临床怎么用

  • CXCL13 ELISA与CXCL13 LFA均可用于确诊LNB患者脑脊液CXCL13检测以支持LNB诊断。
  • 需快速出结果时可优先考虑CXCL13 LFA。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diagnosis of Lyme neuroborreliosis (LNB) is challenging, as long as Borrelia-specific intrathecal antibodies are not yet detectable. The chemokine CXCL13 is elevated in the cerebrospinal fluid (CSF) of LNB patients. Here, we compared the performances of the Euroimmun CXCL13 enzyme-linked immunosorbent assay (CXCL13 ELISA) and the ReaScan CXCL13 lateral flow immunoassay (CXCL13 LFA), a rapid point-of-care test, to support the diagnosis of LNB. In a dual-center case-control study, CSF samples from 90 patients (34 with definite LNB, 10 with possible LNB, and 46 with other central nervous system [CNS] diseases [non-LNB group]) were analyzed with the CXCL13 ELISA and the CXCL13 LFA. Classification of patients followed the European Federation of Neurological Societies (EFNS) guidelines on LNB. The CXCL13 ELISA detected elevated CXCL13 levels in all patients with definite LNB (median, 1,409 pg/ml) compared to the non-LNB controls (median, 20.7 pg/ml; P < 0.0001), with a sensitivity of 100% and a specificity of 84.8% (cutoff value, 78.6 pg/ml; area under the receiver operating characteristic [ROC] curve, 0.93). Similarly, the CXCL13 LFA yielded elevated CXCL13 levels in 31 patients with definite LNB (median arbitrary value, 223.5) compared to the non-LNB control patients (median arbitrary value, 0; P < 0.0001) and had a sensitivity and specificity of 91.2% and 93.5%, respectively (cutoff arbitrary value, 22.5; area under the ROC curve, 0.94). The correlation between the CXCL13 levels obtained by ELISA and LFA was strong (Spearman correlation coefficient r = 0.89; P < 0.0001). The CXCL13 ELISA and the CXCL13 LFA are comparable diagnostic tools for the detection of CXCL13 in the CSF of patients with definite LNB. The advantage of the CXCL13 LFA is the shorter time to result.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Ziegler K, Rath A, Schoerner C, et al. Comparative Analysis of the Euroimmun CXCL13 Enzyme-Linked Immunosorbent Assay and the ReaScan Lateral Flow Immunoassay for Diagnosis of Lyme Neuroborreliosis. J Clin Microbiol. 2020. PMID: 32434781. doi:10.1128/JCM.00207-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。